Celsion Announces Publication of Clinical and Scientific Review of ThermoDox as Treatment for Primary Liver Cancer

Celsion Corporation CLSN announced today the publication of a clinical and scientific review of ThermoDox®, the Company's proprietary heat-activated liposomal encapsulation of doxorubicin, as a treatment for Hepatocellular Carcinoma in the August 2011 issue of Future Oncology. The article, titled "Lyso-Thermosensitive Liposomal Doxorubicin: An Adjuvant to Increase the Cure Rate of Radiofrequency Ablation in Liver Cancer," provides an overview of current standards and investigational approaches to the treatment of HCC, focusing on the curative and synergistic potential of combining lyso-thermosensitive liposomal doxorubicin and RFA as front-line therapy.